Gilead Sciences, Inc. Stock price

Equities

GILD

US3755581036

Pharmaceuticals

Delayed Nasdaq 04:00:00 2023-09-22 pm EDT Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
75.01 USD -0.35% -0.87% -12.63%
Sales 2023 * 26,872 M Sales 2024 * 27,519 M Capitalization 93 788 M
Net income 2023 * 5,763 M Net income 2024 * 6,621 M EV / Sales 2023 *
4,01x
Net Debt 2023 * 14,092 M Net Debt 2024 * 9,430 M EV / Sales 2024 *
3,75x
P/E ratio 2023 *
16,3x
P/E ratio 2024 *
13,9x
Employees -
Yield 2023 *
4,07%
Yield 2024 *
4,25%
Free-Float99.89%
More Fundamentals * Assessed data
Dynamic Chart
Gilead Sciences Gets EU Committee's Positive Opinion on Expanding Veklury's Indication MT
Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury to Treat COVID-19 in People with Hepatic Impairment CI
Gilead Sciences Says Yescarta Meets Primary Endpoint in Phase 2 Study in Patients With Large B-Cell Lymphoma MT
Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma CI
US FDA approves GSK's bone marrow cancer therapy RE
GILEAD SCIENCES, INC. : Ex-dividend day for FA
Transcript : Gilead Sciences, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 11:30 AM CI
North American Morning Briefing: Inflation, -2- DJ
Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer CI
Equity Markets Close Higher Ahead of Next Week's Inflation Report MT
US Equity Markets End Slightly Higher Ahead of Next Week's Inflation Report MT
S&P 500 closes up slightly ahead of key US inflation data RE
US Equity Markets Mixed As Traders Await Inflation Data MT
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon MT
Wall St rises as megacaps gain, yields slip ahead of US inflation data RE
More news
1 day-0.73%
1 week-2.70%
Current month-1.58%
1 month-0.88%
3 months-3.02%
6 months-4.89%
Current year-12.32%
More quotes
1 week
75.14
Extreme 75.14
76.39
1 month
73.25
Extreme 73.25
78.98
Current year
73.25
Extreme 73.25
88.29
1 year
61.45
Extreme 61.445
89.74
3 years
56.56
Extreme 56.56
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 2019
Director of Finance/CFO 53 2019
Chief Tech/Sci/R&D Officer - 2021
Members of the board TitleAgeSince
Director/Board Member 52 2020
Chairman 58 2019
Director/Board Member 68 2009
More insiders
Date Price Change Volume
23-09-22 75.01 -0.35% 4 351 809
23-09-21 75.27 -0.73% 5,272,598
23-09-20 75.82 +0.07% 4,826,589
23-09-19 75.77 +0.20% 4,002,720
23-09-18 75.62 -0.07% 3,337,942

Delayed Quote Nasdaq, September 21, 2023 at 04:00 pm EDT

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.27USD
Average target price
91.36USD
Spread / Average Target
+21.38%
Consensus
1st Jan change Capi. (M$)
-12.32% 93 788 M $
+6.84% 76 262 M $
-17.89% 123 B $
+0.97% 63 659 M $
-8.64% 50 834 M $
+14.09% 137 B $
+14.74% 50 104 M $
-1.15% 50 043 M $
+26.34% 47 593 M $
+2.58% 144 B $
Other Pharmaceuticals
  1. Markets
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
-40% off #SeptemberDeals : Our subscriptions help you find hidden investment opportunities.
Subscribe
fermer